The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 17, 2020
Filed:
Dec. 28, 2017
Applicants:
St. Jude Children's Research Hospital, Inc., Memphis, TN (US);
National University of Singapore, Singapore, SG;
Inventors:
Dario Campana, Singapore, SG;
Yu-Hsiang Chang, Kaohsiung, TW;
Assignees:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., Memphis, TN (US);
NATIONAL UNIVERSITY OF SINGAPORE, Singapore, SG;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); A61K 38/00 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61K 35/17 (2015.01); C12N 5/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0646 (2013.01); A61K 35/17 (2013.01); A61K 38/00 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/7056 (2013.01); C12N 5/0087 (2013.01); C07K 2319/00 (2013.01); C07K 2319/70 (2013.01); C12N 2510/00 (2013.01);
Abstract
The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.